TY - JOUR
T1 - Nonmelanoma Skin Cancer in Patients Older Than Age 85 Years Presenting for Mohs Surgery
T2 - A Prospective, Multicenter Cohort Study
AU - Maisel-Campbell, Amanda
AU - Lin, Katherine A.
AU - Ibrahim, Sarah A.
AU - Kang, Bianca Y.
AU - Anvery, Noor
AU - Dirr, McKenzie A.
AU - Christensen, Rachel E.
AU - Aylward, Juliet L.
AU - Bari, Omar
AU - Bhatti, Hamza
AU - Bolotin, Diana
AU - Cherpelis, Basil S.
AU - Cohen, Joel L.
AU - Condon, Sean
AU - Farhang, Sheila
AU - Firoz, Bahar
AU - Garrett, Algin B.
AU - Geronemus, Roy G.
AU - Golda, Nicholas J.
AU - Humphreys, Tatyana R.
AU - Hurst, Eva A.
AU - Jacobson, Oren H.
AU - Jiang, S. Brian
AU - Karia, Pritesh S.
AU - Kimyai-Asadi, Arash
AU - Kouba, David J.
AU - Lahti, James G.
AU - Council, Martha Laurin
AU - Le, Marilyn
AU - MacFarlane, Deborah F.
AU - Maher, Ian A.
AU - Miller, Stanley J.
AU - Moioli, Eduardo K.
AU - Morrow, Meghan
AU - Neckman, Julia
AU - Pearson, Timothy
AU - Peterson, Samuel R.
AU - Poblete-Lopez, Christine
AU - Prather, Chad L.
AU - Ranario, Jennifer S.
AU - Rubin, Ashley G.
AU - Schmults, Chrysalyne D.
AU - Swanson, Andrew M.
AU - Urban, Christopher
AU - Xu, Y. Gloria
AU - Alam, Murad
AU - Yoo, Simon
AU - Poon, Emily
AU - Harikumar, Vishnu
AU - Weil, Alexandra
AU - Iyengar, Sanjana
AU - Schaeffer, Matthew R.
N1 - Funding Information:
Funding/Support: This study was supported by departmental research funds from the Department of Dermatology at Northwestern University.
Publisher Copyright:
© 2022 American Medical Association. All rights reserved.
PY - 2022/7
Y1 - 2022/7
N2 - Importance: It has been suggested that Mohs surgery for skin cancer among individuals with limited life expectancy may be associated with needless risk and discomfort, along with increased health care costs. Objective: To investigate patient- A nd tumor-specific indications considered by clinicians for treatment of nonmelanoma skin cancer in older individuals. Design, Setting, and Participants: This multicenter, prospective cohort study was conducted using data from US private practice and academic centers. Included patients were those older than age 85 years presenting for skin cancer surgery and referred for Mohs surgery, with reference groups of those younger than age 85 years receiving Mohs surgery and those older than age 85 years not receiving Mohs surgery. Data were analyzed from November 2018 through January 2019. Exposures: Mohs surgery for nonmelanoma skin cancer. Main Outcomes and Measures: Reason for treatment selection. Results: Among 1181 patients older than age 85 years referred for Mohs surgery (724 [61.9%] men among 1169 patients with sex data; 681 individuals aged >85 to 88 years [57.9%] among 1176 patients with age data) treated at 22 sites, 1078 patients (91.3%) were treated by Mohs surgery, and 103 patients (8.7%) received alternate treatment. Patients receiving Mohs surgery were more likely to have tumors on the face (738 patients [68.5%] vs 26 patients [25.2%]; P <.001) and nearly 4-fold more likely to have high functional status (614 patients [57.0%] vs 16 patients [15.5%]; P <.001). Of 15 distinct reasons provided by surgeons for opting to proceed with Mohs surgery, the most common were patient desire for treatment with a high cure rate (712 patients [66.0%]), good or excellent patient functional status for age (614 patients [57.0%]), and high risk associated with the tumor based on histology (433 patients [40.2%]). Conclusions and Relevance: This study found that older patients who received Mohs surgery often had high functional status, high-risk tumors, and tumors located on the face. These findings suggest that timely surgical treatment may be appropriate in older patients given that their tumors may be aggressive, painful, disfiguring, and anxiety provoking..
AB - Importance: It has been suggested that Mohs surgery for skin cancer among individuals with limited life expectancy may be associated with needless risk and discomfort, along with increased health care costs. Objective: To investigate patient- A nd tumor-specific indications considered by clinicians for treatment of nonmelanoma skin cancer in older individuals. Design, Setting, and Participants: This multicenter, prospective cohort study was conducted using data from US private practice and academic centers. Included patients were those older than age 85 years presenting for skin cancer surgery and referred for Mohs surgery, with reference groups of those younger than age 85 years receiving Mohs surgery and those older than age 85 years not receiving Mohs surgery. Data were analyzed from November 2018 through January 2019. Exposures: Mohs surgery for nonmelanoma skin cancer. Main Outcomes and Measures: Reason for treatment selection. Results: Among 1181 patients older than age 85 years referred for Mohs surgery (724 [61.9%] men among 1169 patients with sex data; 681 individuals aged >85 to 88 years [57.9%] among 1176 patients with age data) treated at 22 sites, 1078 patients (91.3%) were treated by Mohs surgery, and 103 patients (8.7%) received alternate treatment. Patients receiving Mohs surgery were more likely to have tumors on the face (738 patients [68.5%] vs 26 patients [25.2%]; P <.001) and nearly 4-fold more likely to have high functional status (614 patients [57.0%] vs 16 patients [15.5%]; P <.001). Of 15 distinct reasons provided by surgeons for opting to proceed with Mohs surgery, the most common were patient desire for treatment with a high cure rate (712 patients [66.0%]), good or excellent patient functional status for age (614 patients [57.0%]), and high risk associated with the tumor based on histology (433 patients [40.2%]). Conclusions and Relevance: This study found that older patients who received Mohs surgery often had high functional status, high-risk tumors, and tumors located on the face. These findings suggest that timely surgical treatment may be appropriate in older patients given that their tumors may be aggressive, painful, disfiguring, and anxiety provoking..
UR - http://www.scopus.com/inward/record.url?scp=85131293551&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85131293551&partnerID=8YFLogxK
U2 - 10.1001/jamadermatol.2022.1733
DO - 10.1001/jamadermatol.2022.1733
M3 - Article
C2 - 35612849
AN - SCOPUS:85131293551
SN - 2168-6068
VL - 158
SP - 770
EP - 778
JO - JAMA dermatology
JF - JAMA dermatology
IS - 7
ER -